Inhibrx is developing antibody-based biotherapeutics to treat many of the most dangerous and clinically relevant bacterial and viral infections. Therapeutics target key virulence factors, pathogen surface antigens or combinations thereof.
Traditionally small molecules were the focus of novel antibiotic discovery campaigns, however, many of the small molecules that show antibacterial activity also show toxicity in people. The toxicity from small molecule drugs is often due to lack of specific binding to the bacterial target and off-target binding to critical human proteins. In contrast, antibodies and other protein-based therapeutics are very specific for their targets due to larger binding interfaces. Therefore, Inhibrxâ€™s antibody-based approach for treating drug resistant bacterial infections should not be hindered by toxicity.
Inhibrxâ€™s infectious disease JET-MABs target and inactivate conserved bacterial virulence factors while recruiting and activating specific immune cells. We developed numerous recruitment modules that specifically bind and activate macrophages, neutrophils and NK cells. Inhibrx tailors the immune recruitment activity of each JET-MAB to address the specific biology of each pathogenic bacteria for maximal efficacy.
Targeting novel bacterial pathways
Existing antibiotics primarily target three general bacterial pathways: cell wall synthesis, nucleic acid synthesis and protein synthesis. The few new antibiotics recently FDA approved fall into the same three pathways and are likely to encounter the same problems of resistance. Novel pathways need to be targeted in order to impede the ability of bacteria to rapidly evolve antibiotic resistance.
Inhibrx is developing antibody therapeutics that specifically target highly conserved virulence factors present in pathogenic bacteria but are absent in normal non-pathogenic flora. By neutralizing key virulence factors and recruiting specific immune cells, we supercharge the natural immune response to clear drug resistant bacterial infections.